Dibenzylxanthines as PPEPCK-M inhibitors for cancer therapy

Marc Aragó, Sergio Rodríguez-Arévalo, Juan Moreno, Sònia Abás, Agnès Figueras, Belén Pérez, Francesc Viñals, María Carmen Escolano, José Carlos Perales

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

Resum

Phosphoenolpyruvate carboxykinase (PEPCK) is the key enzyme in gluconeogenesis/glyceroneogenesis, which catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate. In eukaryotes, there are two isozymes present either in the cytosol (PEPCKC, PCK1) or the mitochondria (PEPCK-M, PCK2). While PCK1 is found in gluconeogenic tissues and has a very clear metabolic function, PCK2 is expressed in non-gluconeogenic cell types, where its role remains largely unknown. For example, PCK2 is highly expressed in most cancer cells, where it provides a growth advantage to cancer cells in nutrient-poor environments.
Idioma originalAnglès
Pàgines (de-a)0001-1
Nombre de pàgines1
RevistaProceedings (MDPI)
Volum22
DOIs
Estat de la publicacióPublicada - 2019

Fingerprint

Navegar pels temes de recerca de 'Dibenzylxanthines as PPEPCK-M inhibitors for cancer therapy'. Junts formen un fingerprint únic.

Com citar-ho